



Metabolic Profiling for Microbial Resistance

Guest Editors:

Prof. Enzo Palombo

Dr. David J. Beale

**Dr. Konstantinos A.
Kouremenos**

Deadline for manuscript
submissions:

closed (31 December 2020)

Message from the Guest Editors

Infectious diseases continue to be a major public health issue. The emergence of new diseases, the re-emergence of old diseases and the increased rates of resistance to antimicrobial agents, such as antibiotics, have led to a great demand for new drugs with novel modes of actions. The WHO has declared that antimicrobial resistance (AMR) *“is an increasingly serious threat to global public health that requires action across all government sectors and society”*. Thus, new strategies are needed to combat AMR. Increased understanding of how AMR develops, new methods to rapidly identify resistant microbes and the development of new drugs with novel modes of actions are urgently required if we are to make an impact. Metabolomics presents an opportunity to apply new technologies to better understand the problems associated with AMR and to develop new and more effective solutions. This special issue will bring together current information relevant to AMR and illustrate how innovative metabolomics approaches can help us to address a major health problem. We invite you to be part of this exciting project.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
X@antibioticsmdpi